Richard Adler, MD, FACS, discusses corneal fluorescein staining data presented at AAO 2023 from the pooled analysis of 2 phase 3 studies.
This is a video synopsis/summary of a Post Conference Perspectives featuring Richard Adler, MD.
Adler discusses phase 3 trial results for Miebo (perfluorohexyloctane ophthalmic solution), a drug being evaluated for treatment of evaporative dry eye disease in patients with meibomian gland dysfunction.
The phase 3 study compared Miebo (perfluorohexyloctane ophthalmic solution) to a vehicle for the ability to improve signs and symptoms of dry eye. Signs were assessed by corneal staining. After 4 weeks of treatment, Miebo (perfluorohexyloctane ophthalmic solution) demonstrated statistically significant improvements in both signs and symptoms compared with the vehicle, which were sustained through 8 weeks.
Adler notes Miebo produced rapid effects by targeting evaporation, a mechanism of action not previously explored for dry eye treatment. With a favorable safety profile and novel mechanism, Miebo offers an important new treatment option for dry eye disease.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More